Deubiquitinating enzyme UCHL1 stabilizes CAV1 to inhibit ferroptosis and enhance docetaxel resistance in nasopharyngeal carcinoma. (PubMed, Anticancer Drugs) - Apr 27, 2025 - "Additionally, treatment with the ferroptosis inducer erastin could counteract the effects of CAV1 overexpression on drug resistance. UCHL1 interacted with CAV1 and inhibited its ubiquitin-mediated degradation pathway. By deubiquitinating CAV1, UCHL1 stabilizes and increases its expression, which inhibits ferroptosis and enhances the resistance of NPC cells to docetaxel."
Journal • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • Targeted Protein Degradation • CAV1 • UCHL1
|
|
Daquan Wu; Fengrong Tang; Guanghui Hou; Na Shen; Peng Wang; Yixian Ye
|